Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Leizorovicz, A. Cohen, A. Turpie, C. Olsson, P. Vaitkus, S. Goldhaber (2004)
Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical PatientsCirculation, 110
A. Falanga, M. Donati (2001)
Pathogenesis of Thrombosis in Patients with MalignancyInternational Journal of Hematology, 73
F. Fraisse, L. Holzapfel, JEAN-MICHEL Couland, G. Simonneau, B. Bedock, M. Feissel, P. Herbecq, Reginald Pordes, J. Poussel, Louis Roux (2000)
Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France.American journal of respiratory and critical care medicine, 161 4 Pt 1
M. Hillbom, T. Erilä, K. Sotaniemi, T. Tatlisumak, S. Sarna, M. Kaste (2002)
Enoxaparin vs heparin for prevention of deep‐vein thrombosis in acute ischaemic stroke: a randomized, double‐blind studyActa Neurologica Scandinavica, 106
F. Fraisse, L. Holzapfel, J.-M. Coulaud (2000)
Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPDAm J Respir Crit Care Med, 161
H. Otten, M. Prins, Susanne Smorenburg, B. Hutten (2000)
Risk Assessment and Prophylaxis of Venous Thromboembolism in Non-Surgical Patients: Cancer as a Risk FactorPathophysiology of Haemostasis and Thrombosis, 30
D. Grady, N. Wenger, D. Herrington, Steven Khan, C. Furberg, D. Hunninghake, E. Vittinghoff, S. Hulley (2000)
Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement StudyAnnals of Internal Medicine, 132
S. Goldhaber, F. Grodstein, M. Stampfer, J. Manson, G. Colditz, F. Speizer, W. Willett, C. Hennekens (1997)
A prospective study of risk factors for pulmonary embolism in women.JAMA, 277 8
E. Daly, M. Vessey, R. Painter, M. Hawkins (1996)
Case-control study of venous thromboembolism risk in users of hormone replacement therapyThe Lancet, 348
A. Handley (1972)
Low-dose heparin after myocardial infarction.Lancet, 2 7778
W. Miehsler, W. Reinisch, E. Valic, W. Osterode, W. Tillinger, T. Feichtenschlager, J. Grisar, K. Machold, S. Scholz, H. Vogelsang, G. Novacek (2004)
Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?Gut, 53
J. Cade, J. Andrews, A. Stubbsi (1982)
Comparison of sodium and calcium heparin in prevention of venous thromboembolism.Australian and New Zealand journal of medicine, 12 5
S. Hulley, C. Furberg, E. Barrett-Connor, J. Cauley, D. Grady, W. Haskell, R. Knopp, M. Lowery, S. Satterfield, H. Schrott, E. Vittinghoff, D. Hunninghake (2002)
Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).JAMA, 288 1
W. Ageno, A. Squizzato, F. Ambrosini, F. Dentali, C. Marchesi, Valentina Mera, L. Steidl, A. Venco (2002)
Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns.Haematologica, 87 7
C.J. Carter, J.G. Kelton, J. Hirsh (1982)
The relationship between haemorrhagic and antithrombotic properties of LMWH and heparinsBlood, 59
C. Ibarra-Pérez, Enrique Lau-Cortés, S. Colmenero-Zubiate, N. Arévila-Ceballos, J. Fong, R. Sánchez-Martínez, María Dominguez, J. Elizalde-González (1988)
Prevalence and Prevention of Deep Venous Thrombosis of the Lower Extremities in High-Risk Pulmonary PatientsAngiology, 39
A. Turpie, K. Bauer, B. Eriksson, M. Lassen (2002)
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.Archives of internal medicine, 162 16
M. Samama (2000)
An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study.Archives of internal medicine, 160 22
G. Leone, S. Sica, P. Chiusolo, L. Teofili, V. Stefano (2001)
Blood cells diseases and thrombosis.Haematologica, 86 12
F. Anderson, H. Wheeler, R. Goldberg, D. Hosmer, Ann Forcier, N. Patwardhan (1991)
Physician practices in the prevention of venous thromboembolism.Annals of internal medicine, 115 8
A. Nicolaides (1997)
Prevention of Venous Thromboembolism: International Consensus Statement
A.T. Cohen, B.L. Davidson, A.S. Gallus (2003)
Fondaparinux for the prevention of VTE in acutely ill medical patients [abstract]Blood, 102
C. Carter, J. Kelton, J. Hirsh, A. Cerskus, A. Santos, M. Gent (1982)
The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits.Blood, 59 6
E. Lechler, W. Schramm, C. Flosbach (1996)
The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group.Haemostasis, 26 Suppl 2
D. Sutherland, I. Weitz, H. Liebman (2003)
Thromboembolic complications of cancer: Epidemiology, pathogenesis, diagnosis, and treatmentAmerican Journal of Hematology, 72
W. Geerts, G. Pineo, J. Heit, D. Bergqvist, M. Lassen, C. Colwell, J. Ray (2004)
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest, 126 3 Suppl
J. Belch, G. Lowe, A. Ward, C. Forbes, C. Prentice (1981)
Prevention of Deep Vein Thrombosis in Medical Patients by Low-Dose HeparinScottish Medical Journal, 26
C. Warlow, G. Terry, A. Kenmure, A. Beattie, D. Ogston, A. Douglas (1973)
A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction.Lancet, 2 7835
L.C. Marras, W.H. Geerts, J.R. Perry (2000)
The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based reviewCancer, 89
F.-X. Kleber, C. Witt, G. Vogel (2003)
A randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease: THE-PRINCE study groupAm Heart J, 145
E. Daly, M. Vessey, M. Hawkins, J. Carson, Parimala Gough, S. Marsh (1996)
Risk of venous thromboembolism in users of hormone replacement therapyThe Lancet, 348
G. Anderson, E. Hull (1950)
The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure.American heart journal, 39 5
A. Cohen, R. Edmondson, M. Phillips, V. Ward, V. Kakkar (1996)
The changing pattern of venous thromboembolic disease.Haemostasis, 26 2
M. Donati (1994)
Cancer and thrombosis.Haemostasis, 24 2
A. Lloyd, P. Anderson, D.J. Quinlan (2000)
Economic evaluation of prophylaxis of venous thromboembolism in acute medical patients with enoxaparin in the UK [abstract no. 3659]Blood, 96
A. Kierkegaard, L. Norgren, C. Olsson, J. Castenfors, G. Persson, S. Persson (2009)
Incidence of deep vein thrombosis in bedridden non-surgical patients.Acta medica Scandinavica, 222 5
P Sandercock, A. Belt, Richard Lindley, J. Slattery (1993)
Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials.Journal of Neurology, Neurosurgery & Psychiatry, 56
D. Sandler, J. Martin (1989)
Autopsy Proven Pulmonary Embolism in Hospital Patients: Are We Detecting Enough Deep Vein Thrombosis?Journal of the Royal Society of Medicine, 82
M.M. Samama, A.T. Cohen, J.-Y. Darmon (1999)
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patientsN Engl J Med, 341
R. Alikhan, A. Cohen, S. Combe, M. Samama, L. Desjardins, A. Eldor, C. Janbon, A. Leizorovicz, C. Olsson, A. Turpie (2003)
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX studyBlood Coagulation & Fibrinolysis, 14
F. Kleber, C. Witt, G. Vogel, K. Koppenhagen, U. Schomaker, C. Flosbach (2003)
Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.American heart journal, 145 4
J. Arcelus, S. Candocia, C. Traverso, F. Fábrega, J. Caprini, Hasty Jh (1991)
Venous thromboembolism prophylaxis and risk assessment in medical patients.Seminars in thrombosis and hemostasis, 17 Suppl 3
S. Hulley (2002)
Noncardiovascular disease outcomes during 6.8 years of hormone therapy : Heart and Estrogen/Progestin Study fellow-up (HERS II)JAMA, 288
Icrf, Bhf, Radcliffe Infirmary, Oxford (1994)
Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patientsBMJ, 308
G. Motykie, J. Caprini, J. Arcelus, L. Zebala, C. Lee, N. Finke, A. Tamhane, J. Reyna (2000)
Risk factor assessment in the management of patients with suspected deep venous thrombosis.International angiology : a journal of the International Union of Angiology, 19 1
A. Nicolaides, J. Fareed, A. Kakkar, Breddin Hk, S. Goldhaber, R. Hull, V. Kakkar, J. Michiels, K. Myers, M. Samama, A. Sasahara, E. Kalodiki (2006)
Prevention and treatment of venous thromboembolism - International Consensus Statement (Guidelines according to scientific evidence)International Angiology, 25
P. Emerson, P. Marks (1977)
Preventing thromboembolism after myocardial infarction: effect of low-dose heparin or smoking.British Medical Journal, 1
R. Alikhan, A. Cohen, S. Combe, M. Samama, L. Desjardins, A. Eldor, C. Janbon, A. Leizorovicz, C. Olsson, A. Turpie (2004)
Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study.Archives of internal medicine, 164 9
M. Laffan, E. Tuddenham (1998)
Assessing thrombotic riskBMJ, 317
P. Mismetti, S. Laporte-simitsidis, B. Tardy, M. Cucherat, A. Buchmüller, D. Juillard-Delsart, H. Décousus (2000)
Prevention of Venous Thromboembolism in Internal Medicine with Unfractionated or Low-molecular-weight Heparins: A Meta-analysis of Randomised Clinical TrialsThrombosis and Haemostasis, 83
J. Cade (1982)
High risk of the critically ill for venous thromboembolismCritical Care Medicine, 10
Hairul Ahmad, A. Geissler, D. Maclellan (2002)
Deep venous thrombosis prophylaxis: Are guidelines being followed?ANZ Journal of Surgery, 72
G. Gensini, D. Prisco, M. Falciani, M. Comeglio, A. Colella (1997)
Identification of Candidates for Prevention of Venous ThromboembolismSeminars in Thrombosis and Hemostasis, 23
M. Samama, A. Cohen, J. Darmon, L. Desjardins, A. Eldor, C. Janbon, A. Leizorovicz, Hélène Nguyen, C. Olsson, A. Turpie, N. Weisslinger (1999)
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.The New England journal of medicine, 341 11
M. Laffan, E. Tuddenham (1998)
Science, medicine, and the future: assessing thrombotic risk.BMJ, 317 7157
Heparin Group, B. Gårdlund (1996)
Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseasesThe Lancet, 347
K. Bauer (2001)
The Thrombophilias: Well-Defined Risk Factors with Uncertain Therapeutic ImplicationsAnnals of Internal Medicine, 135
S. Bates (2002)
Treatment and prophylaxis of venous thromboembolism during pregnancy.Thrombosis research, 108 2-3
K. Sperry, C. Key, R. Anderson (1990)
Toward a population-based assessment of death due to pulmonary embolism in New Mexico.Human pathology, 21 2
D. Clarke‐Pearson, I. Synan, R.Edward Colemen, W. Hinshaw, W. Creasman (1984)
The natural history of postoperative venous thromboemboli in gynecologic oncology: a prospective study of 382 patients.American journal of obstetrics and gynecology, 148 8
John Benfield (2006)
Prevention of Venous Thromboembolism
W.H. Geerts, J.A. Heit, G.P. Clagett (2004)
Prevention of venous thromboembolism: Seventh ACCP recommendationsChest, 126
M. Levine, G. Raskob, S. Landefeld, C. Kearon (1992)
Hemorrhagic complications of anticoagulant treatment.Chest, 114 5 Suppl
C. Esquivel, D. Bergqvist, C. Björck, B. Nilsson (1982)
Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo.Thrombosis research, 28 3
S. Haas (2002)
Venous Thromboembolic Risk and Its Prevention in Hospitalized Medical Patients, 28
J. Bergmann, S. Mouly (2002)
Thromboprophylaxis in Medical Patients: Focus on FranceSEMINARS IN THROMBOSIS AND HEMOSTASIS, 28
A.N. Nicolaides, H.K. Breddin, J. Fareed (2001)
Prevention of venous thromboembolism: international consensus statement guidelines compiled in accordance with the scientific evidenceInt Angiol, 20
E. Daly, M.P. Vessey, R. Painter (1996)
Case-control study of venous thromboembolism in users of hormone replacement therapy [letter]Lancet, 348
P. Disdier, B. Granel, J. Serratrice, J. Constans, U. Michon-Pasturel, E. Hachulla, C. Conri, B. Devulder, L. Swiader, P. Piquet, A. Branchereau, J. Jouglard, G. Moulin, P. Weiller (2001)
Cannabis Arteritis RevisitedAngiology, 52
M. Abdollahi, M. Cushman, F. Rosendaal (2003)
Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive useThrombosis and Haemostasis, 89
L. Marras, W. Geerts, J. Perry (2000)
The risk of venous thromboembolism is increased throughout the course of malignant gliomaCancer, 89
B. Lindblad, N. Sternby, D. Bergqvist (1991)
Incidence of venous thromboembolism verified by necropsy over 30 years.British Medical Journal, 302
C.O. Esquivel, D. Bergqvist, C.-G. Bjork (1982)
Comparison between commercial heparin, LMWH and pentosan polysulphate on haemostasis and platelets in vivoThromb Res, 28
N.A. Reynolds, C.M. Perry, L.J. Scott (2004)
Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgeryDrugs, 64
S. Prescott, K. Richards, G. Tikoff, J. Armstrong, J. Shigeoka (2015)
Venous thromboembolism in decompensated chronic obstructive pulmonary disease. A prospective study.The American review of respiratory disease, 123 1
David Mohr, T. Petterson, Christine Lohse, W. O'Fallon, L. Melton, J. Heit, Marc Silverstein (2001)
The Epidemiology of Venous Thromboembolism in the CommunityThrombosis and Haemostasis, 86
A. Cohen, R. Galanello, A. Piga, V. Sanctis, F. Tricta (2003)
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.Blood, 102 5
M.-M. Samama (2000)
An epidemiologic study of risk factors for deep vein thrombosis in medical outpatientsArch Intern Med, 160
Acutely ill general medical patients are at moderate-to-high risk of venous thromboembolism (VTE); approximately 10–30% may develop deep vein thrombosis or pulmonary embolism, the latter being a leading contributor to deaths in hospital.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 20, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.